Suppr超能文献

基于细胞的筛选有助于酵母展示发现真正的细胞结合配体:针对肿瘤血管生物标志物 CD276。

Cellular-Based Selections Aid Yeast-Display Discovery of Genuine Cell-Binding Ligands: Targeting Oncology Vascular Biomarker CD276.

机构信息

Department of Chemical Engineering and Materials Science , University of Minnesota-Twin Cities , Minneapolis , Minnesota 55455 , United States.

Department of Radiology , Stanford University , Palo Alto , California 94305 , United States.

出版信息

ACS Comb Sci. 2019 Mar 11;21(3):207-222. doi: 10.1021/acscombsci.8b00156. Epub 2019 Jan 24.

Abstract

Yeast surface display is a proven tool for the selection and evolution of ligands with novel binding activity. Selections from yeast surface display libraries against transmembrane targets are generally carried out using recombinant soluble extracellular domains. Unfortunately, these molecules may not be good models of their true, membrane-bound form for a variety of reasons. Such selection campaigns often yield ligands that bind a recombinant target but not target-expressing cells or tissues. Advances in cell-based selections with yeast surface display may aid the frequency of evolving ligands that do bind true, membrane-bound antigens. This study aims to evaluate ligand selection strategies using both soluble target-driven and cellular selection techniques to determine which methods yield translatable ligands most efficiently and generate novel binders against CD276 (B7-H3) and Thy1, two promising tumor vasculature targets. Out of four ligand selection campaigns carried out using only soluble extracellular domains, only an affibody library sorted against CD276 yielded translatable binders. In contrast, fibronectin domains against CD276 and affibodies against CD276 were discovered in campaigns that either combined soluble target and cellular selection methods or used cellular selection methods alone. A high frequency of non target-specific ligands discovered from the use of cellular selection methods alone motivated the development of a depletion scheme using disadhered, antigen-negative mammalian cells as a blocking agent. Affinity maturation of CD276-binding affibodies by error-prone PCR and helix walking resulted in strong, specific cellular CD276 affinity ( K = 0.9 ± 0.6 nM). Collectively, these results motivate the use of cellular selections in tandem with recombinant selections and introduce promising affibody molecules specific to CD276 for further applications.

摘要

酵母表面展示技术是一种经过验证的工具,可用于选择和进化具有新型结合活性的配体。针对跨膜靶标的酵母表面展示文库的选择通常使用重组可溶性细胞外结构域进行。然而,由于各种原因,这些分子可能不是其真实的膜结合形式的良好模型。此类选择活动通常会产生与重组靶标结合但不与表达靶标的细胞或组织结合的配体。利用酵母表面展示的基于细胞的选择技术的进步可能有助于提高进化配体与真实的膜结合抗原结合的频率。本研究旨在评估使用可溶性靶标驱动和细胞选择技术的配体选择策略,以确定哪种方法最有效地产生可转化的配体,并针对两个有前途的肿瘤血管目标 CD276(B7-H3)和 Thy1 产生新的结合物。在仅使用可溶性细胞外结构域进行的四次配体选择活动中,只有针对 CD276 的亲和体文库产生了可转化的结合物。相比之下,针对 CD276 的纤连蛋白结构域和针对 CD276 的亲和体是在结合了可溶性靶标和细胞选择方法或仅使用细胞选择方法的活动中发现的。单独使用细胞选择方法发现的非靶标特异性配体的高频率促使开发了一种耗尽方案,该方案使用去黏附的、抗原阴性的哺乳动物细胞作为阻断剂。通过易错 PCR 和螺旋行走对 CD276 结合亲和体进行亲和力成熟,导致强烈、特异性的细胞 CD276 亲和力( K = 0.9 ± 0.6 nM)。总的来说,这些结果促使人们在重组选择的基础上使用细胞选择,并引入针对 CD276 的有前途的亲和体分子,以进一步应用。

相似文献

引用本文的文献

本文引用的文献

9
Cancer biomarker discovery: current status and future perspectives.癌症生物标志物的发现:现状与未来展望。
Int J Radiat Biol. 2014 Aug;90(8):659-77. doi: 10.3109/09553002.2014.892229. Epub 2014 May 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验